HDFCCC Member Update

member announcement for 10/20/2014
[ view online | correct or unsubscribe ]

News   |   Upcoming events   |  Funding Opps   |  Notes

News


From UCSF.edu


HDFCCC In the MEDIA

Featured events

HDFCCC Programmatic Events Other Cancer Events Conferences, Symposia, Retreats

FROM THE NCI:

REQUEST FOR PROJECT TEAM MEMBER APPLICATIONS FOR DESIGNING CLINICAL TRIALS USING VX-970 (NSC 780162)

Deadline: Tuesday, October 28, 2014 at 5 PM (ET).

The Experimental Therapeutics Clinical Trials Network (ETCTN), will employ a team science approach for drug development, while integrating research resources and programs across the NCI. Teams will work together to define the best path forward for the development of new drugs. This team science approach should allow NCI-sponsored investigators to perform high impact clinical trials enriched with molecular characterization of patients and sophisticated scientific research. The goal is to move toward the more precise selection of patients for participation on clinical studies and involve all members of the ETCTN in efficient and timely trial completion. Along the way we hope to enhance interaction and collaboration as well as improving the training of the next generation of drug developers.

The Project Team Member Application (PTMA) for VX-970, a potent inhibitor of ataxia telangiectasia mutated and Rad3-related (ATR) kinase, is a part of the new CTEP ETCTN process. The PTMA attached to this email replaces the former Mass Solicitation and is intended to enable CTEP to identify investigators who will be invited to participate in the VX-970 Drug Development Team. Clinical, translational, and basic scientists will convene to discuss the VX-970 draft development plan and to modify it as needed. Dr. Alice Chen will lead the team along with one of the investigators chosen through the PTMA process.
Reference materials: Deadline: Tuesday, October 28, 2014 at 5 PM (ET).



Funding Opportunities

OTHER FUNDING NOTES:

Current Limited Submission Opportunities (Applications through LSO office)

Misc Notes

UCSF-HDFCCC Karen Gehrman, Communications
415.353.4471 (voice) | communications@cc.ucsf.edu




CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and privileged information for the use of the designated recipient/s named above. Distribution, reproduction or any other use of this transmission by any party other than the intended recipient/s is prohibited.